GTHX Historical Income Statement
| GTHX Stock | USD 3.99 0.20 4.77% |
Historical analysis of G1 Therapeutics income statement accounts such as Selling General Administrative of 46.9 M or Total Revenue of 86.6 M can show how well G1 Therapeutics performed in making a profits. Evaluating G1 Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of G1 Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining G1 Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether G1 Therapeutics is a good buy for the upcoming year.
GTHX |
About GTHX Income Statement Analysis
G1 Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to G1 Therapeutics shareholders. The income statement also shows GTHX investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
G1 Therapeutics Income Statement Chart
G1 Therapeutics Income Statement is one of the three primary financial statements used for reporting GTHX's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of G1 Therapeutics revenue and expense. G1 Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, G1 Therapeutics' Interest Expense is fairly stable compared to the past year. Total Revenue is likely to rise to about 86.6 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 291.2 K in 2024. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of G1 Therapeutics. It is also known as G1 Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from G1 Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into G1 Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in G1 Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.At this time, G1 Therapeutics' Interest Expense is fairly stable compared to the past year. Total Revenue is likely to rise to about 86.6 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 291.2 K in 2024.
G1 Therapeutics income statement Correlations
Click cells to compare fundamentals
G1 Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
G1 Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 356K | 410K | (303K) | 1.3M | 513K | 291.2K | |
| Selling General Administrative | 40.0M | 68.5M | 97.7M | 104.2M | 79.5M | 46.9M | |
| Total Revenue | 2.1M | 45.3M | 31.5M | 51.3M | 82.5M | 86.6M | |
| Gross Profit | (356K) | 45.3M | 29.5M | 47.6M | 75.3M | 79.1M | |
| Other Operating Expenses | 129.0M | 141.8M | 173.9M | 187.5M | 122.0M | 105.4M | |
| Operating Income | (129.0M) | (96.5M) | (142.5M) | (136.2M) | (39.5M) | (41.5M) | |
| Net Income From Continuing Ops | (122.4M) | (99.3M) | (148.4M) | (147.6M) | (70.7M) | (74.3M) | |
| Ebit | (129.0M) | (96.5M) | (142.5M) | (136.2M) | (39.5M) | (41.5M) | |
| Research Development | 89.0M | 73.3M | 76.2M | 83.3M | 43.7M | 58.6M | |
| Ebitda | (128.7M) | (96.1M) | (142.8M) | (134.9M) | (39.0M) | (41.0M) | |
| Cost Of Revenue | 356K | 0.0 | 2.0M | 3.7M | 7.2M | 6.8M | |
| Total Operating Expenses | 129.0M | 141.8M | 171.9M | 183.7M | 114.8M | 103.5M | |
| Income Before Tax | (122.4M) | (97.8M) | (147.4M) | (145.9M) | (44.9M) | (47.1M) | |
| Total Other Income Expense Net | 6.6M | (1.4M) | (5.0M) | (9.7M) | (5.3M) | (5.1M) | |
| Net Income Applicable To Common Shares | (122.4M) | (99.3M) | (148.4M) | (147.6M) | (132.8M) | (126.2M) | |
| Net Income | (122.1M) | (99.3M) | (148.4M) | (147.6M) | (48.0M) | (50.4M) | |
| Income Tax Expense | (356K) | 1.4M | 925K | 1.7M | 3.1M | 1.8M | |
| Reconciled Depreciation | 356K | 582K | 469K | 530K | 526K | 428.5K | |
| Non Operating Income Net Other | 6.6M | (1.4M) | (5.0M) | (9.7M) | (8.7M) | (8.3M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards G1 Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, G1 Therapeutics' short interest history, or implied volatility extrapolated from G1 Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in G1 Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.Note that the G1 Therapeutics information on this page should be used as a complementary analysis to other G1 Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for GTHX Stock analysis
When running G1 Therapeutics' price analysis, check to measure G1 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy G1 Therapeutics is operating at the current time. Most of G1 Therapeutics' value examination focuses on studying past and present price action to predict the probability of G1 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move G1 Therapeutics' price. Additionally, you may evaluate how the addition of G1 Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is G1 Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of G1 Therapeutics. If investors know GTHX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about G1 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.93) | Revenue Per Share 1.595 | Quarterly Revenue Growth 0.451 | Return On Assets (0.16) | Return On Equity (0.92) |
The market value of G1 Therapeutics is measured differently than its book value, which is the value of GTHX that is recorded on the company's balance sheet. Investors also form their own opinion of G1 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is G1 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because G1 Therapeutics' market value can be influenced by many factors that don't directly affect G1 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between G1 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if G1 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, G1 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.